Clin Oncol | Volume 5, Issue 1 | Research Article | Open Access

Relationship between Expression of β-Tubulin-III Plus ERCC1 in Advanced Ovarian Cancer and Chemotherapy Sensitivity of Paclitaxel Plus Platin Chemotherapy

Yufei Fan1*, Maomao Wang1, Dinggang Li2 and David Kerr3

1Department of Oncology, Beijing Yanhua Hospital, China 2Department of Oncology, Beijing Haidian Hospital, China 3Department of Medicine, University of Oxford, Oxford, UK

*Correspondance to: Yufei Fan 

Fulltext PDF

Abstract

Objective: Ovarian cancer is one of the three major malignancies in the female reproductive system. Its histological types are numerous, and early diagnosis is difficult. Although surgery and radiotherapy and chemotherapy have made great progress, mortality still ranks first among female reproductive system malignancies, which seriously threatens gynecological cancer patient's life. To explore the expression of β-tubulin-III plus ERCC1 in advanced ovarian cancer and analyze its correlation with the chemotherapeutic effect of paclitaxel docetaxel plus cisplatin or carboplatin. Patients and Methods: Sixty-four chemotherapy patients with advanced ovarian cancer were treated with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) and cisplatinum (75 mg/m2) or carboplatin (AUC5) days. Expression of β-tubulin-III and ERCC1 in 64 cases of ovarian cancer were detected by immunohistochemical method. According to the different expression of Tubulin III and ERCC1, the patients were divided into 2 groups, and then statistical analysis of the efficiency was conducted between the 2 groups. Efficiency rate, Progression Free Survival (PFS) and Overall Survival (OS) were analyzed. The effect of age, staging, and peritoneal metastasis on survival was analyzed using COX regression. Results: Overall response rate is 76.6% (49/64), ERCC1+ group: Chemotherapy Overall Response Rate (ORR) is 50.0% (9/18). ERCC1- group: Chemotherapy ORR is 87% (40/46). The response rate between the two groups was significantly different and was statistically significant, P value <0.05. ERCC1+ group: Mean Progression Free Survival (PFS) is 12.3 ± 11.4 months. ERCC1- group: Mean Progression Free Survival (PFS) is 21.7 ± 23.3 months. There was significant difference between the two groups P value <0.05. ERCC1+ group: Overall Survival (OS) is 22.1 ± 16.1 months. ERCC1- group: Mean Overall Survival (OS) is 38.2 ± 34.6 months. The Overall Survival (OS) between the two groups was significantly different and was statistically significant, P value <0.05. β-Tubulin III- group: Chemotherapy ORR is 89% (31/35), β-Tubulin III+ group: Chemotherapy ORR is 62% (18/29), the response rate between the two groups was significantly different and was statistically significant, P value <0.05. β-Tubulin III- group: Mean Progression Free Survival (PFS) is 27 ± 26 months. β-Tubulin III+: Mean Progression Free Survival (PFS) is 9.6 ± 5.3 months. The Progression Free Survival (PFS) between the two groups was significantly different and was statistically significant, P value <0.05. β-Tubulin III- group: Mean Overall Survival (OS) is 44.8 ± 37.6 months. β-Tubulin III+ group mean Overall Survival (OS) is 20.3 ± 12 months. The Overall Survival (OS) between the two groups was significantly different and was statistically significant, P<0.05. Conclusion: Detection of the expression of β-tubulin-III and ERCC1 before chemotherapy may predict the sensitivity of ovarian cancer to paclitaxel and Platinum drugs.

Keywords:

β-Tubulin-III and ERCC1; Ovarian cancer; Chemosensitivity; Chemotherapy

Citation:

Fan Y, Wang M, Li D, Kerr D. Relationship between Expression of β-Tubulin-III Plus ERCC1 in Advanced Ovarian Cancer and Chemotherapy Sensitivity of Paclitaxel Plus Platin Chemotherapy. Clin Oncol. 2020; 5: 1697..

Subscribe to Our Newsletter